ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1980

Sparsentan for Treatment of Pediatric Patients with Selected Proteinuric Glomerular Diseases: Design of the Phase 2 EPPIK Study

Session Information

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology

Authors

  • Trachtman, Howard, NYU School of Medicine, New York, New York, United States
  • Saleem, Moin, University of Bristol & Bristol Royal Hospital for Children, Bristol, United Kingdom
  • Coppo, Rosanna, Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy
  • Rheault, Michelle N., University of Minnesota Medical School Twin Cities, Minneapolis, Minnesota, United States
  • He, Ping, Travere Therapeutics Inc, San Diego, California, United States
  • Komers, Radko, Travere Therapeutics Inc, San Diego, California, United States
Background

Sparsentan is a novel Dual Endothelin Angiotensin Receptor Antagonist (DEARA) being investigated for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). It is a dual acting, highly selective antagonist of both the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). The Phase 2 EPPIK study will examine the long-term antiproteinuric and nephroprotective potential and safety of sparsentan in pediatric patients with FSGS, minimal change disease (MCD), IgAN, IgA vasculitis (IgAV), and Alport syndrome (AS).

Methods

The global, open-label, single-arm, multicenter study will evaluate the safety, efficacy, and pharmacokinetics (PK) of sparsentan in ~57 patients (aged ≥1 to <18 years), including ~30 with FSGS and/or MCD (population 1) and ~27 with IgAN, IgAV, or AS (population 2) over 108 weeks (Figure). See Table for inclusion/exclusion criteria. Sparsentan will be administered in a novel liquid formulation at a dose adjusted to body weight.

Results

Primary endpoints include safety (incidence of treatment-emergent adverse events) and change in urine protein/creatinine ratio (UP/C) from baseline over 108 weeks of sparsentan treatment. Secondary endpoints include PK outcomes, change from baseline over 108 weeks in albumin/creatinine ratio and eGFR, and the proportion of patients with FSGS/MCD who achieve partial remission (UP/C ≤1.5 g/g and >40% reduction in UP/C).

Conclusion

This Phase 2 study will evaluate the long-term safety, antiproteinuric, and nephroprotective effects of sparsentan in pediatric patients.

Table. Key Inclusion and Exclusion Criteria
Inclusion All: eGFR ≥30 mL/min/1.73m2; mean seated blood pressure 5th to 95th percentile for age/sex/height
Population 1: Male/female age ≥1 and <18 years; UP/C ≥1.5 g/g at screening despite history or ongoing corticosteroid/immunosuppressive drugs; biopsy-proven FSGS/MCD or FSGS/MCD-associated genetic mutation in a podocyte protein
Population 2: Male/female age ≥2 and <18 years; UP/C ≥1.0 g/g at screening; biopsy-confirmed IgAN/IgAV nephritis or AS-associated genetic mutation
Exclusion All: Weighs <7.3 kg at screening; secondary FSGS/MCD/IgAN/IgAV; significant cardiovascular or hepatic conditions; new immunosuppressive therapy within 6 months of screening or not on stable dose of chronic therapy ≥1 month before screening

Funding

  • Commercial Support